Prevalence and factors associated with the presence of abnormal function liver tests in patients with ulcerative colitis

Annals of Hepatology

Volumn 9, Issue 4, 2010, Pages 397-401

  Yamamoto Furusho, Jesús K ^a   Sánchez Osorio, Magdalena ^a   Uribe, Misael ^a  

^a Department of Gastroenterology   (Canada)

Author keywords

Abnormal; Inflammatory bowel disease; Liver tests; Ulcerative colitis

Indexed keywords

AZATHIOPRINE; GLUCOCORTICOID; INFLIXIMAB; MESALAZINE; SALAZOSULFAPYRIDINE;

ABNORMAL LABORATORY RESULT; ADULT; ARTICLE; AUTOIMMUNE HEPATITIS; CHOLESTATIC HEPATITIS; COLON RESECTION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; ECHOGRAPHY; FATTY LIVER; FEMALE; HEPATITIS C; HUMAN; HYPERTRANSAMINASEMIA; LIVER BIOPSY; LIVER FUNCTION TEST; LIVER GRANULOMA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MEXICO; PARENTERAL NUTRITION; PHENOTYPE; PROSPECTIVE STUDY; RISK FACTOR; SCLEROSING CHOLANGITIS; SEPSIS; ULCERATIVE COLITIS; ADOLESCENT; HEPATITIS; LIVER; PATHOPHYSIOLOGY; PREVALENCE; RETROSPECTIVE STUDY;

ADOLESCENT; ADULT; CHOLANGITIS, SCLEROSING; COLECTOMY; COLITIS, ULCERATIVE; FATTY LIVER; FEMALE; HEPATITIS; HUMANS; LIVER; LIVER FUNCTION TESTS; MALE; MEXICO; PREVALENCE; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; RISK FACTORS; SEPSIS; YOUNG ADULT;

EID: 79952318286     PISSN: 16652681     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1665-2681(19)31615-1     Document Type: Article

References (24)

1. Bargiggia S, Maconi G, Elli M, et al. Sonographic prevalence of liver steatosis and biliary tract stones in patients with inflammatory bowel disease: study of 511 subjects at a single center. J Clin Gastroenterol 2003; 36: 417-420.
2. Wewer V, Gluud C, Schlichting P, et al. Prevalence of hepa-tobiliary dysfunction in a regional group of patients with chronic inflammatory bowel disease. Scand J Gastroente-rol 1991; 26: 97-102.
3. Rasmussen HH, Fallingborg JF, Mortensen PB, et al. Hepa-tobiliary dysfunction and primary sclerosing cholangitis in patients with Crohn's disease. Scand J Gastroenterol 1997; 32: 604-610.
4. Loftus EVJ, Sandborn WJ, Lindor KD, et al. Interactions between chronic liver disease and inflammatory bowel disease. Inflamm Bowel Dis 1997; 3: 288-302.
5. Satsangi J, Silverberg MS, Vermiere S, Colombel JF. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006; 55: 749-753.
6. Truelove SC, Witts LJ. Cortisone in ulcerative colitis; preliminary report on a therapeutic trial. Br Med J 1954; 2: 375-378.
7. Yamamoto-Furusho JK, Torijano-Carrera E. Intestinal Protozoa Infections among Patients with Ulcerative Colitis: Prevalence and Impact on Clinical Disease Course. Digestion 2010; 82: 18-23.
8. Thapa BR, Walia A. Liver Function tests and their interpretation. Ind J Pediatrics 2007; 74: 663-671.
9. Wewer V, Gluud C, Schlichting P, et al. Prevalence of hepa-tobiliary dysfunction in a regional group of patients with chronic inflammatory bowel disease. Scand J Gastroente-rol 1991; 26: 97-102.
10. Rasmussen HH, Fallingborg JF, Mortensen PB, et al. Hepa-tobiliarydysfunction and primary sclerosing cholangitis in patients with Crohn's disease. Scand J Gastroenterol 1997; 32: 604-610.
11. Shepherd HA, Selby WS, Chapman RW, et al. Ulcerative colitis and persistent liver dysfunction. Q J Med 1983; 52: 503-513.
12. Broome U, Glaumann H, Hellers G, et al. Liver disease in ul-cerativecolitis: an epidemiological and follow up study in the county of Stockholm. Gut 1994; 35: 84-89.
13. Heikius B, Niemela S, Lehtola J, et al. Hepatobiliary and coexisting pancreatic duct abnormalities in patients with inflammatory bowel disease. Scand J Gastroenterol 1997; 32: 153-161.
14. Mikkola K, Kiviluoto T, Riihela M, et al. Liver involvement and its course in patients operated on for ulcerative colitis. Hepatogastroenterology 1995; 42: 68-72.
15. Boberg KM, Schrumpf E, Fausa O, et al. Hepatobiliary disease inulcerative colitis. An analysis of 18 patients with hepatobiliary lesions classified as small-duct primary sclerosing cholangitis. Scand J Gastroenterol 1994; 29: 744-752.
16. Perrett AD, Higgins G, Johnston HH, et al. The liver in ul-cerative colitis. Q J Med 1971; 40: 211-238.
17. De Fazio C, Torgano G, de Franchis R, et al. Detection of liver involvementin inflammatory bowel disease by abdominal ultrasound scan. Int J Clin Lab Res 1992; 21: 314-317.
18. Riegler G, D'Inca R, Sturniolo GC, et al. Hepatobiliary alterations in patients with inflammatory bowel disease: a mul-ticenter study. Caprilli & Gruppo Italiano Studio Colon-Retto. Scand J Gastroenterol 1998; 33: 93-98.
19. Dew MJ, Thompson H, Allan RN. The spectrum of hepatic dysfunction in inflammatory bowel disease. QJI Med 1979; 148: 113-115.
20. Bengoa JM, Hanauer SB, Sitrin MD, Baker AL, Rosenberg IH. Pattern and prognosis of liver function tests abnormalities during parenteral nutrition in inflammatory bowel disease. Hepatology 1985; 5: 79-84.
21. Eade MN. Liver disease in ulcerative colitis. Ann Intern Med 1970; 72: 475-487.
22. Bargiggia S, Maconi G, Elli M, et al. Sonographic prevalence of liver steatosis and biliary tract stones in patients with inflammatory bowel disease: study of 511 subjects at a single center. J Clin Gastroenterol 2003; 36: 417-420.
23. Ozdil S, Akyuz F, Pinarbasi B, et al. Ulcerative colitis: analyses of 116 cases (do extraintestinal manifestations effect the time to catch remission?). Hepatogastroente-rology 2004; 51: 768-770.
24. Broomé U, Glaumann H, Hellers G, Nilsson B, Sörstad J, Hul-tcrantz R. Liver disease in ulcerative colitis: an epidemio-logical and follow up study in the county of Stockholm. Gut 1994; 35: 84-89.